Wedbush Upgrades Sarepta To Outperform As 'FDA Comes Up With Option C' By: Benzinga via Benzinga June 07, 2016 at 08:57 AM EDT The FDA has requested Sarepta Therapeutics Inc (NASDAQ: SRPT) for dystrophin data in the ongoing evaluation of the eteplirsen New ... Read More >> Related Stocks: Sarepta Therapeutics